title: Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium.
abstract: Immediately after the annual scientific meeting of the American Society of Hematology (ASH), a select group of clinical and laboratory investigators in myeloproliferative neoplasms (MPN) is summoned to a post-ASH conference on chronic myeloid leukemia and the BCR-ABL1-negative MPN. The 6th such meeting occurred on December 13–14,2011, in La Jolla, California, USA, under the direction of its founder,Dr. Tariq Mughal. The current document is the first of two reports on this post-ASH event and summarizes the most recent preclinical and clinical advances in polycythemia vera, essential thrombocythemia,and primary myelofibrosis.
authors.affiliation: Leukemia Service and Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. abdelwao@mskcc.org
authors.forename: Omar
authors.initials: O
authors.lastname: Abdel-Wahab
authors.forename: Animesh
authors.initials: A
authors.lastname: Pardanani
authors.forename: Olivier A
authors.initials: OA
authors.lastname: Bernard
authors.forename: Guido
authors.initials: G
authors.lastname: Finazzi
authors.forename: John D
authors.initials: JD
authors.lastname: Crispino
authors.forename: Heinz
authors.initials: H
authors.lastname: Gisslinger
authors.forename: Robert
authors.initials: R
authors.lastname: Kralovics
authors.forename: Olatoyosi
authors.initials: O
authors.lastname: Odenike
authors.forename: Kapil
authors.initials: K
authors.lastname: Bhalla
authors.forename: Vikas
authors.initials: V
authors.lastname: Gupta
authors.forename: Giovanni
authors.initials: G
authors.lastname: Barosi
authors.forename: Jason
authors.initials: J
authors.lastname: Gotlib
authors.forename: Paola
authors.initials: P
authors.lastname: Guglielmelli
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Kiladjian
authors.forename: Pierre
authors.initials: P
authors.lastname: Noel
authors.forename: Mario
authors.initials: M
authors.lastname: Cazzola
authors.forename: Alessandro M
authors.initials: AM
authors.lastname: Vannucchi
authors.forename: Ronald
authors.initials: R
authors.lastname: Hoffman
authors.forename: Tiziano
authors.initials: T
authors.lastname: Barbui
authors.forename: Juergen
authors.initials: J
authors.lastname: Thiele
authors.forename: Richard A
authors.initials: RA
authors.lastname: Van Etten
authors.forename: Tariq
authors.initials: T
authors.lastname: Mughal
authors.forename: Ayalew
authors.initials: A
authors.lastname: Tefferi
mesh_terms: D002986:Clinical Trials as Topic; D019175:DNA Methylation; D004273:DNA, Neoplasm / Q000737:chemistry / Q000235:genetics; D018450:Disease Progression; D015507:Drugs, Investigational / Q000627:therapeutic use; D052138:Genes, Neoplasm; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000473:pathology; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use; D006801:Humans; D007249:Inflammation; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics; D015337:Multicenter Studies as Topic; D009196:Myeloproliferative Disorders / Q000188:drug therapy / Q000235:genetics*; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000235:genetics; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011379:Prognosis; D011994:Recombinant Proteins / Q000627:therapeutic use; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D004273:DNA, Neoplasm; D015507:Drugs, Investigational; D056572:Histone Deacetylase Inhibitors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D009363:Neoplasm Proteins; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D013792:Thalidomide; C467566:pomalidomide; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a